There are 2789 resources available
1048P - Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Presenter: Jeeyun Lee
Session: ePoster Display
1049P - Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
Presenter: Florentia Dimitriou
Session: ePoster Display
1188P - Concurrent chemoradiotherapy with cisplatin + S-1 for locally advanced non-small cell lung cancer: IPD meta-analysis
Presenter: Yuri Taniguchi
Session: ePoster Display
1189P - EGFR mutation p.747_749del enhances anlotinib sensitivity by upregulating EGR1 and DUSP6 in NSCLC cells
Presenter: yu limeng
Session: ePoster Display
1190TiP - SKYSCRAPER-03: Phase III, open-label randomised study of atezolizumab + tiragolumab vs durvalumab in patients with locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) who have not progressed after platinum-based concurrent chemoradiation (cCRT)
Presenter: Rafal Dziadziuszko
Session: ePoster Display
1195P - Brigatinib (BRG) vs crizotinib (CRZ) in ALK TKI–naive ALK+ NSCLC: Final results from ALTA-1L
Presenter: Sanjay Popat
Session: ePoster Display
1196P - Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK+ advanced non-small cell lung cancer (NSCLC)
Presenter: Ben Solomon
Session: ePoster Display
1159P - Individualized methylation-based dynamic analysis of cell-free DNA in postoperative monitoring of resected lung cancer
Presenter: Kezhong Chen
Session: ePoster Display
1160P - Efficacy and biomarker identification of neoadjuvant chemo-immunotherapy in potentially resectable non-small cell lung cancer
Presenter: Yongchang Zhang
Session: ePoster Display
1161P - Can 18F-FDG-PET/CT predict PD-L1 expression in resected non-small cell lung cancer (NSCLC)?
Presenter: Daniel Hughes
Session: ePoster Display